Bio-Rad Laboratories (BIO) reported $2.6B in revenue for fiscal 2025, +0.7% year on year. That ranks #1190 by revenue among 2853 SEC filers and #192 in Technology. Net income was $760M, a net margin of 29.4%. Revenue has grown 2.5% a year on average since 2016 ($2.1B then). The fiscal 2025 balance sheet shows $10.6B in total assets, $530M in cash and $1.2B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $2.6B | +0.7% | FY20252025-12-31 |
| Gross profitGrossProfit | $1.3B | −2.8% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $47.2M | −82.5% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $760M | +$2.6B | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $532M | +16.9% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $158M | −4.8% | FY20252025-12-31 |
| Total assetsAssets | $10.6B | +12.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $7.5B | +13.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $530M | +8.5% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $1.2B | +0.1% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $592M | −$527M | Open → |
| Q2 20262026-06-30 | $651M | $371M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 28 of 298 companies compared | 29.4% | |
| Operating marginRank 229 of 297 companies compared | 1.8% | |
| R&D as share of revenueRank 140 of 253 companies compared | 10.7% | |
| Cash as share of revenueRank 146 of 297 companies compared | 20.5% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Bio-Rad Laboratories, Inc.
- Ticker
- BIO
- Exchange
- NYSE
- SIC classification
- Laboratory Analytical Instruments (3826)
- Fiscal year end
- 12-31
- CIK
- 0000012208
Filings
- 10-QAug 4, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KFeb 13, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Rackspace TechnologyRXT | $2.7B | −$226M |
| ZscalerZS | $2.7B | −$41.5M |
| WexWEX | $2.7B | $304M |
| Bio-Rad LaboratoriesBIO | $2.6B | $760M |
| Zillow GroupZG | $2.6B | $23.0M |
| UbiquitiUI | $2.6B | $712M |
| NutanixNTNX | $2.5B | $188M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Bio-Rad Laboratories — Key figures |url=https://companiesranked.com/en/company/bio-rad-laboratories |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Bio-Rad Laboratories — Key figures. CompaniesRanked. https://companiesranked.com/en/company/bio-rad-laboratoriesBibTeX
@misc{companiesranked-en-company-bio-rad-laboratories-2026,
author = {{CompaniesRanked}},
title = {{Bio-Rad Laboratories — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/bio-rad-laboratories}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000012208-26-000010 · February 13, 2026
{{cite web |title=Bio-Rad Laboratories — Key figures — 10-K (0000012208-26-000010) |url=https://www.sec.gov/Archives/edgar/data/12208/000001220826000010/bio-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-13}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.